🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: PH FDC SC

Found 12 matching trials

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

PHASE3

This is a Phase IIIb, multinational, multicenter, randomized, open-label st...

Status

Completed

Location

Centro de Investigaciones Médicas y Desarrollo LC S.R.L

Start Date

2022-07-05

Trial ID

NCT05415215

Treatments Being Tested

Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)Pertuzumab IV Trastuzumab IV Trastuzumab Emtansine Investigator's Choice of Chemotherapy Surgery Radiotherapy

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

PHASE2

This is a Phase II, randomized, multicentre, multinational, open-label, cro...

Status

Completed

Location

Rocky Mountain Cancer Center - Lakewood (West)

Start Date

2018-12-19

Trial ID

NCT03674112

Treatments Being Tested

Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)Pertuzumab IV Trastuzumab IV

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

PHASE2

This is a multicenter, open-label, single-arm, one-stage, phase II study to...

Status

Active Not Recruiting

Location

UMHAT Sveti Ivan Rilski EAD Department of Medical Oncology

Start Date

2021-08-05

Trial ID

NCT04733118

Treatments Being Tested

Trastuzumab and Pertuzumab (FDC SC) and T-DM1

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

PHASE3

This study will evaluate the pharmacokinetics, efficacy, and safety of the ...

Status

Completed

Location

Peking University People's Hospital

Start Date

2020-02-05

Trial ID

NCT04024462

Treatments Being Tested

Pertuzumab IV Trastuzumab IV Pertuzumab and Trastuzumab FDC SC Doxorubicin Cyclophosphamide Docetaxel Surgery Post-Operative Radiotherapy Hormone Therapy

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

PHASE3

This Phase III, randomized, two-arm, open-label, multicenter study will eva...

Status

Active Not Recruiting

Location

Arizona Clinical Research Center, Inc

Start Date

2022-07-18

Trial ID

NCT05296798

Treatments Being Tested

Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocrine Therapy of Investigator's Choice

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

PHASE2

The study consists of a screening period of 28 days, a treatment period. Lo...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2025-12-15

Trial ID

NCT07245797

Treatments Being Tested

fixed-dose combination of pertuzumab and trastuzumab as subcutaneousformulation q3w and nab-paclitaxel in 3-week cycle for total 6 cycles with inavolisib (6 cycles) or without inavolisib.

An Observational, Multicenter Study Evaluating the Safety of ReAl-lifePertuzumab and Trastuzumab Fixed Dose Combination: the RAPID Study

N/A

This is a single arm prospective, observational multi-centre study in patie...

Status

Completed

Location

A.O.R.N. San Giuseppe Moscati

Start Date

2023-10-03

Trial ID

NCT06835348

A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

PHASE1

This is a randomized, open-label, 2-arm, parallel-group, single-dose, multi...

Status

Completed

Location

Q-Pharm Pty Ltd; Nucleus Network Brisbane Clinic

Start Date

2022-05-30

Trial ID

NCT05275010

Treatments Being Tested

Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)Handheld Syringe with Hypodermic Needle On-Body Delivery System

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

PHASE1

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study i...

Status

Recruiting

Location

City of Hope

Start Date

2021-06-22

Trial ID

NCT04802759

Treatments Being Tested

Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

PHASE2

Evaluation of the potential incremental efficacy and safety of inavolisib i...

Status

Recruiting

Location

KEM Kliniken Essen-Mitte

Start Date

2023-01-02

Trial ID

NCT05306041

Treatments Being Tested

Inavolisib PHESGO Endocrine therapy

Previous Next